Bionor Pharma’s First Reboost Vacc-4x Study Accepted for Publication in the Vaccine Journal
(Oslo, Norway, 7 August 2013) Bionor Pharma ASA (OSE: BIONOR) announces that the results from the Company’s first re-boost clinical trial of Vacc-4x have been accepted for publication in the renowned journal Vaccine.
The Phase II trial was conducted at Oslo University Hospital and completed in 2010. The trial investigated the effect of re-boosting 22 available patients from previous study with the Company’s leading therapeutic HIV vaccine candidate Vacc-4x. The study demonstrated that it is possible to elicit strong memory immune responses up to 7 years after the initial vaccination.
The results formed the scientific rationale for the Company’s current Phase II Vacc-4x Reboost trial. The study investigates whether the elicited memory immune responses can reduce viral load even further. The trial expects to read out Q1 2014.
For the article authored by Professor Dag Kvale at Oslo University Hospital and his research team and Bionor Pharma, click here.
Bionor Pharma ASA
Synne H Røine